Successful lipid-complexed amphotericin B treatment of Candida arthritis in a lymphoma patient.
Fungal arthritis is uncommon but has been increasingly diagnosed over recent years, particularly in patients with immunodeficiency due for instance to hematological malignancies. Candida albicans is the most frequent causative agent, and the knee is the joint most often involved. Amphotericin B is the drug of choice, but is associated with significant toxicity. Recently developed lipid formulations of amphotericin B have been found as effective and less toxic than the conventional formulation. We report a new case of Candida arthritis that occurred after chemotherapy for nonHodgkin's lymphoma and was successfully treated with lipid-complexed amphotericin B.
Azaceta
G
G
Department of Hematology, Saragossa Teaching Hospital, Spain.
Olave
T
T
de los Martires
L D
LD
Delgado
C
C
Gutierrez
M
M
Palomera
L
L
D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage; D001170:Arthritis, Infectious / Q000188:drug therapy* / Q000209:etiology; D002177:Candidiasis / Q000150:complications* / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000150:complications*; D016896:Treatment Outcome
D000935:Antifungal Agents; D000666:Amphotericin B